- In June 2024, BIOMÉRIEUX received FDA approval for its BIOFIRE SPOTFIRE platform, designed for point-of-care (POC) testing for respiratory infections and sore throat conditions. This innovative platform aims to enhance rapid diagnosis and improve patient management by delivering timely results in clinical settings
- In May 2024, Cipla announced a strategic investment agreement with Achira Labs Private Limited, a company focused on the commercialization of point-of-care test kits in India. This collaboration aims to expand access to advanced diagnostic solutions and address healthcare needs in the region
- In March 2023, Health Canada granted approval to bioLytical Laboratories Inc. for its INSTI Multiplex HIV-1/2 Syphilis Antibody Test. This test is designed to provide rapid and accurate results, facilitating timely treatment and management of sexually transmitted infections
- In November 2022, LumiraDx Healthcare, based in the UK, introduced its highly sensitive C - reactive protein (CRP) point-of-care (POC) antigen test throughout India. This POC CRP test is applicable in various clinical environments and aims to minimize unnecessary antibiotic prescriptions that contribute to antimicrobial resistance (AMR)
- In October 2022, Genes2Me Pvt. Ltd. unveiled the Rapi-Q Point of Care RT PCR solution for detecting human papillomavirus (HPV) and tuberculosis. This user-friendly device provides rapid results in under 45 minutes and is CE-IVD marked, ensuring superior performance, high sensitivity, and reliable detection
Frequently Asked Questions
The market is segmented based on Global Primary Care POC Diagnostics Market Segmentation By Platform (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, and Immunoassays), Prescription (Prescription-Based Testing and OTC Testing), End-User (Professional Diagnostic Centers, Home Care, Research Laboratories, and Other End Users), Product (Glucose, Cardio-Metabolic, Infectious Disease, Coagulation, Pregnancy and Fertility, Tumor/Cancer Marker, Urinalysis, Cholesterol, Hematology, Drugs-of-Abuse, Fecal Occult, and Other POC Products) – Industry Trends and Forecast to 2031
.
The Global Primary Care Poc Diagnostics Market size was valued at USD 17.30 USD Billion in 2023.
The Global Primary Care Poc Diagnostics Market is projected to grow at a CAGR of 6.2% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
